Clinical Trials Directory

Trials / Sponsors / Genfleet Therapeutics (Shanghai) Inc.

Genfleet Therapeutics (Shanghai) Inc.

Industry · 11 registered clinical trials — 7 currently recruiting.

StatusTrialPhaseStarted
Not Yet RecruitingPhase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Can
Metastatic Pancreatic Cancer
Phase 32025-12-01
RecruitingA Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12
Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)
Phase 1 / Phase 22025-10-21
Not Yet RecruitingA Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced
Cancer, PDAC, CRC (Colorectal Cancer)
Phase 1 / Phase 22025-09-22
WithdrawnA Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer
Phase 22025-08-01
RecruitingA Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia
Cancer Cachexia
Phase 12025-04-24
RecruitingA Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations
KRAS G12D Mutations, Advanced Solid Tumors
Phase 1 / Phase 22024-07-09
RecruitingA Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Large B-cell Lymphoma
Phase 1 / Phase 22024-03-20
RecruitingA Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1 / Phase 22023-09-06
CompletedA Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mut
Advance Non-small Cell Lung Cancer
Phase 1 / Phase 22023-04-25
CompletedA Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemorad
NSCLC, Stage III
Phase 22022-09-09
CompletedA Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Advanced Solid Tumor
Phase 1 / Phase 22021-10-20